QUETIAPINE probably leads to lower adverse effects: 1. Sedation compared with CLOZAPINE ‐ all data short term (moderate certainty).
QUETIAPINE showed no clear difference in adverse effects: 1. Sedation compared with OLANZAPINE (moderate certainty).
QUETIAPINE led to higher adverse effects: 1. Sedation compared with RISPERIDONE; GRADE not reported.
QUETIAPINE may leads to higher adverse effects: 1. Sedation compared with ZIPRASIDONE (low certainty).
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic ‐ weight gain compared with CLOZAPINE ‐ all data short term (low certainty).
QUETIAPINE probably leads to lower adverse effects: 3. Metabolic ‐ weight significant gain compared with OLANZAPINE (moderate certainty).
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic weight gain ≥7% of total body weight compared with PALIPERIDONE (moderate certainty).
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic weight gain ≥7% of total body weight compared with RISPERIDONE (moderate certainty).
QUETIAPINE probably leads to higher adverse effects: 3. Metabolic weight gain ≥7% of total body weight compared with ZIPRASIDONE (moderate certainty).
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic ‐ weight gain ≥7% of total body weight compared with ARIPIPRAZOLE (low certainty).
QUETIAPINE probably leads to lower adverse effects: 2. Extrapyramidal effects use of antiparkinson… compared with PALIPERIDONE (moderate certainty).
QUETIAPINE probably leads to lower adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson… compared with RISPERIDONE (moderate certainty).
QUETIAPINE may leads to lower adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson… compared with ZIPRASIDONE (low certainty).
QUETIAPINE showed no clear difference in adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson… compared with ARIPIPRAZOLE (low certainty).
The review found no eligible studies for this question.